Biomarkers in MS #MSBlog #MSResearch
“The following is my platform presentation from yesterday on biomarkers. I attempted to make it relevant to clinicians rather than focus on the science. Most of the attendees at ECTRIMS are jobbing neurologists.”
“The following is my platform presentation from yesterday on biomarkers. I attempted to make it relevant to clinicians rather than focus on the science. Most of the attendees at ECTRIMS are jobbing neurologists.”
TIL today I learned that if you're misdiagnosed and prescribed the wrong drug, you might end up with fatal capillary leak syndrome. It just keeps getting better…I didn't know that you could predict who would develop autoimmunity after alem (and then not treating those patients with alem or at least know the risk).
Unfortunately, the biomarkers predicting autoimmunity post alemtuzumab have not panned out in the phase 3 or CARE-MS programme.